These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 26560703)

  • 1. [Survival benefit from the addition of bevacizumab to first-line radiochemotherapy for the treatment of proneural glioblastoma?].
    Seidel C; Kortmann RD
    Strahlenther Onkol; 2016 Jan; 192(1):65-6. PubMed ID: 26560703
    [No Abstract]   [Full Text] [Related]  

  • 2. Can We Predict Bevacizumab Responders in Patients With Glioblastoma?
    Mayer TM
    J Clin Oncol; 2015 Sep; 33(25):2721-2. PubMed ID: 26195699
    [No Abstract]   [Full Text] [Related]  

  • 3. Patients With Proneural Glioblastoma May Derive Overall Survival Benefit From the Addition of Bevacizumab to First-Line Radiotherapy and Temozolomide: Retrospective Analysis of the AVAglio Trial.
    Sandmann T; Bourgon R; Garcia J; Li C; Cloughesy T; Chinot OL; Wick W; Nishikawa R; Mason W; Henriksson R; Saran F; Lai A; Moore N; Kharbanda S; Peale F; Hegde P; Abrey LE; Phillips HS; Bais C
    J Clin Oncol; 2015 Sep; 33(25):2735-44. PubMed ID: 26124478
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Reply to T.J. Kruser et al.
    Chinot OL; Taphoorn MJ; Bais C; Bourgon R; Phillips HS; Abrey LE; Wick W; Mason W; Henriksson R; Saran F; Nishikawa R; Cloughesy T
    J Clin Oncol; 2016 Apr; 34(11):1282-3. PubMed ID: 26884575
    [No Abstract]   [Full Text] [Related]  

  • 5. Identification of Patients Who Benefit From Bevacizumab in High-Grade Glioma-An Easy Question Turned Difficult: Treat the Scan or the Patient?
    Kruser TJ; Mehta MP; Kozak KR
    J Clin Oncol; 2016 Apr; 34(11):1281-2. PubMed ID: 26884565
    [No Abstract]   [Full Text] [Related]  

  • 6. Neuro-oncology: What is the optimal use of bevacizumab in glioblastoma?
    Desjardins A
    Nat Rev Neurol; 2015 Aug; 11(8):429-30. PubMed ID: 26195258
    [No Abstract]   [Full Text] [Related]  

  • 7. Dynamic susceptibility contrast MRI measures of relative cerebral blood volume as a prognostic marker for overall survival in recurrent glioblastoma: results from the ACRIN 6677/RTOG 0625 multicenter trial.
    Schmainda KM; Zhang Z; Prah M; Snyder BS; Gilbert MR; Sorensen AG; Barboriak DP; Boxerman JL
    Neuro Oncol; 2015 Aug; 17(8):1148-56. PubMed ID: 25646027
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Bevacizumab for glioblastoma multiforme after traumatic subarachnoid hemorrhage.
    Lukas RV; Goldenberg F; Nicholas MK
    J Clin Neurosci; 2012 Sep; 19(9):1310-1. PubMed ID: 22721885
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Radiochemotherapy in patients with primary glioblastoma comparing two temozolomide dose regimens: is the survival really so impressive?: in regard to Combs et al. (Int J Radiat Oncol Biol Phys 2008;71:999-1005).
    Jalali R
    Int J Radiat Oncol Biol Phys; 2008 Dec; 72(5):1622; author reply 1622-3. PubMed ID: 19028293
    [No Abstract]   [Full Text] [Related]  

  • 10. Phase II study of concurrent radiation therapy, temozolomide, and bevacizumab followed by bevacizumab/everolimus as first-line treatment for patients with glioblastoma.
    Hainsworth JD; Shih KC; Shepard GC; Tillinghast GW; Brinker BT; Spigel DR
    Clin Adv Hematol Oncol; 2012 Apr; 10(4):240-6. PubMed ID: 22706484
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Relative cerebral blood volume is a potential predictive imaging biomarker of bevacizumab efficacy in recurrent glioblastoma.
    Kickingereder P; Wiestler B; Burth S; Wick A; Nowosielski M; Heiland S; Schlemmer HP; Wick W; Bendszus M; Radbruch A
    Neuro Oncol; 2015 Aug; 17(8):1139-47. PubMed ID: 25754089
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Temozolomide for malignant brain tumours.
    Batchelor T
    Lancet; 2000 Apr; 355(9210):1115-6. PubMed ID: 10791369
    [No Abstract]   [Full Text] [Related]  

  • 13. Long-term Results of a Survey of Prolonged Adjuvant Treatment with Temozolomide in Patients with Glioblastoma (SV3 Study).
    Rivoirard R; Falk AT; Chargari C; Guy JB; Mery B; Nuti C; Peoc'h M; Forest F; Garin C; Adjabi A; Hoarau D; Kawaye S; Almokhles H; Fournel P; Magné N
    Clin Oncol (R Coll Radiol); 2015 Aug; 27(8):486-7. PubMed ID: 25963856
    [No Abstract]   [Full Text] [Related]  

  • 14. Current and Future Drug Treatments for Glioblastomas.
    Ohba S; Hirose Y
    Curr Med Chem; 2016; 23(38):4309-4316. PubMed ID: 27758718
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Temozolomide in patients with a glioblastoma multiforme: new developments].
    Bromberg JE; Postma TJ
    Ned Tijdschr Geneeskd; 2005 Jun; 149(25):1376-8. PubMed ID: 15997689
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Use of angioneogenesis inhibitor monoclonal antibody following standard therapy in recurrent or progressive glioblastoma multiforme].
    Pikó B; Bassam A; Nagy KA; Török E; Vághy R; Vargáné Tamás R; Puskásné Szatmári K
    Magy Onkol; 2012 Sep; 56(3):166-70. PubMed ID: 23008824
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Recent advances in the medical treatment of glioma-temozolomide].
    Nishikawa R
    No To Shinkei; 2006 Dec; 58(12):1035-41. PubMed ID: 17193953
    [No Abstract]   [Full Text] [Related]  

  • 18. Bevacizumab in glioblastoma--still much to learn.
    Fine HA
    N Engl J Med; 2014 Feb; 370(8):764-5. PubMed ID: 24552324
    [No Abstract]   [Full Text] [Related]  

  • 19. The fallacy of single-agent chemotherapy for cancer.
    Friedman HS; Maxwell J
    J Clin Oncol; 2007 Aug; 25(23):3550; author reply 3550-1. PubMed ID: 17687162
    [No Abstract]   [Full Text] [Related]  

  • 20. A pilot study of primary temozolomide chemotherapy and deferred radiotherapy in elderly patients with glioblastoma.
    Chamberlain MC; Chalmers L
    J Neurooncol; 2007 Apr; 82(2):207-9. PubMed ID: 17019532
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.